{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(2)"],"submitter":["Murayama N"],"pubmed_abstract":["Thyroid transcription factor-1 (TTF-1) expression has been associated with the prognosis of patients with non-small cell lung cancer treated with immune checkpoint inhibitor (ICI) therapy; however, it has also been suggested that there is no such link. The present study analyzed the association of TTF-1 expression, evaluated using a cocktail antibody (TTF-1/napsin A; clone, SPT24/TMU-Ad02), with survival after the initiation of ICI therapy in patients with EGFR/ALK wild-type non-squamous non-small cell lung cancer receiving first-line treatment with ICI monotherapy or chemoimmunotherapy. A total of 49 patients were enrolled to the present study. Multivariate analysis using the Cox proportional hazard model showed that TTF-1 expression was associated with progression-free survival (PFS) aft"],"journal":["Molecular and clinical oncology"],"pagination":["11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690345"],"repository":["biostudies-literature"],"pubmed_title":["TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy."],"pmcid":["PMC12690345"],"pubmed_authors":["Seto Z","Tokui K","Hashizume M","Murayama N","Furukawa D","Imanishi S","Hayashi R","Takagi K","Hirabayashi K","Takata N","Inomata M","Miwa T","Okazawa S"],"additional_accession":[]},"is_claimable":false,"name":"TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy.","description":"Thyroid transcription factor-1 (TTF-1) expression has been associated with the prognosis of patients with non-small cell lung cancer treated with immune checkpoint inhibitor (ICI) therapy; however, it has also been suggested that there is no such link. The present study analyzed the association of TTF-1 expression, evaluated using a cocktail antibody (TTF-1/napsin A; clone, SPT24/TMU-Ad02), with survival after the initiation of ICI therapy in patients with EGFR/ALK wild-type non-squamous non-small cell lung cancer receiving first-line treatment with ICI monotherapy or chemoimmunotherapy. A total of 49 patients were enrolled to the present study. Multivariate analysis using the Cox proportional hazard model showed that TTF-1 expression was associated with progression-free survival (PFS) aft","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-06T01:31:20.187Z","creation":"2026-05-24T03:11:09.636Z"},"accession":"S-EPMC12690345","cross_references":{"pubmed":["41383350"],"doi":["10.3892/mco.2025.2920"]}}